LIXT
Lixte Biotechnology Holdings, Inc.
Biotechnology
Market Cap$25M
5Y Perf.-91.7%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
LIXT vs CASI
Revenue, margins, valuation, and 5-year total return — side by side.
CASI
CASI Pharmaceuticals, Inc.
Biotechnology
Market Cap$2M
5Y Perf.-99.1%
LIXT vs CASI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | LIXT | CASI |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $25M | $2M |
| Revenue (TTM) | $0.00 | $27M |
| Net Income (TTM) | $-4M | $-49M |
| Gross Margin | — | 35.8% |
| Operating Margin | — | -168.0% |
| Total Debt | $0.00 | $22M |
| Cash & Equiv. | $1M | $13M |
LIXT vs CASI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
LIXT
CASI
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Lixte Biotechnology… (LIXT) | 100 | 8.3 | -91.7% |
| CASI Pharmaceutical… (CASI) | 100 | 0.9 | -99.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LIXT vs CASI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: LIXT leads in 3 of 5 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. CASI Pharmaceuticals, Inc. is the stronger pick specifically for dividend income and shareholder returns and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
LIXT
Lixte Biotechnology Holdings, Inc.
The Income Pick
LIXT carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 0 yrs, beta 1.09
- EPS growth 40.2%
- -38.9% 10Y total return vs CASI's -98.9%
Best for: income & stability and growth exposure
CASI
CASI Pharmaceuticals, Inc.
The Income Pick
CASI is the clearest fit if your priority is dividends and efficiency.
- 31.1% yield; the other pay no meaningful dividend
- -131.5% ROA vs LIXT's -178.1%
Best for: dividends and efficiency
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | LIXT | 66.2% revenue growth vs CASI's -15.8% |
| Quality / Margins | LIXT | 0.6% margin vs CASI's -183.9% |
| Dividends | CASI | 31.1% yield; the other pay no meaningful dividend |
| Momentum (1Y) | LIXT | +272.9% vs CASI's -91.6% |
| Efficiency (ROA) | CASI | -131.5% ROA vs LIXT's -178.1% |
LIXT vs CASI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2019
LIXT vs CASI — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLLIXTLAGGINGCASI
CASICASI Pharmaceuticals,…
1leads
LIXTLixte Biotechnology H…
2leads
6 Total Categories
CATEGORYLEADERvs CASIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
LIXT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CASI4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
LIXT6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
LIXT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CASI and LIXT operate at a comparable scale, with $27M and $0 in trailing revenue.
| Metric | LIXTLixte Biotechnolo… | CASICASI Pharmaceutic… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $27M |
| EBITDAEarnings before interest/tax | -$3M | -$44M |
| Net IncomeAfter-tax profit | -$4M | -$49M |
| Free Cash FlowCash after capex | -$3M | $0 |
| Gross MarginGross profit ÷ Revenue | — | +35.8% |
| Operating MarginEBIT ÷ Revenue | — | -168.0% |
| Net MarginNet income ÷ Revenue | — | -183.9% |
| FCF MarginFCF ÷ Revenue | — | -103.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -60.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +25.0% | -23.6% |
LIXT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — LIXT and CASI each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | LIXTLixte Biotechnolo… | CASICASI Pharmaceutic… |
|---|---|---|
| Market CapShares × price | $25M | $2M |
| Enterprise ValueMkt cap + debt − cash | $24M | $11M |
| Trailing P/EPrice ÷ TTM EPS | -2.77x | -0.06x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 0.08x |
| Price / BookPrice ÷ Book value/share | 11.96x | 1.25x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — LIXT and CASI each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
CASI leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
LIXT delivers a -2.2% return on equity — every $100 of shareholder capital generates $-2 in annual profit, vs $-3 for CASI. On the Piotroski fundamental quality scale (0–9), CASI scores 2/9 vs LIXT's 1/9, reflecting mixed financial health.
| Metric | LIXTLixte Biotechnolo… | CASICASI Pharmaceutic… |
|---|---|---|
| ROE (TTM)Return on equity | -2.2% | -3.0% |
| ROA (TTM)Return on assets | -178.1% | -131.5% |
| ROICReturn on invested capital | — | -153.0% |
| ROCEReturn on capital employed | -148.2% | -104.6% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 2 |
| Debt / EquityFinancial leverage | — | 11.96x |
| Net DebtTotal debt minus cash | -$1M | $9M |
| Cash & Equiv.Liquid assets | $1M | $13M |
| Total DebtShort + long-term debt | $0 | $22M |
| Interest CoverageEBIT ÷ Interest expense | -419.37x | -66.88x |
CASI leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
LIXT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LIXT five years ago would be worth $1,560 today (with dividends reinvested), compared to $91 for CASI. Over the past 12 months, LIXT leads with a +272.9% total return vs CASI's -91.6%. The 3-year compound annual growth rate (CAGR) favors LIXT at -6.6% vs CASI's -60.8% — a key indicator of consistent wealth creation.
| Metric | LIXTLixte Biotechnolo… | CASICASI Pharmaceutic… |
|---|---|---|
| YTD ReturnYear-to-date | +14.6% | -81.6% |
| 1-Year ReturnPast 12 months | +272.9% | -91.6% |
| 3-Year ReturnCumulative with dividends | -18.5% | -94.0% |
| 5-Year ReturnCumulative with dividends | -84.4% | -99.1% |
| 10-Year ReturnCumulative with dividends | -38.9% | -98.9% |
| CAGR (3Y)Annualised 3-year return | -6.6% | -60.8% |
LIXT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — LIXT and CASI each lead in 1 of 2 comparable metrics.
Risk & Volatility
CASI is the less volatile stock with a -0.12 beta — it tends to amplify market swings less than LIXT's 1.09 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LIXT currently trades 70.3% from its 52-week high vs CASI's 4.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | LIXTLixte Biotechnolo… | CASICASI Pharmaceutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.09x | -0.12x |
| 52-Week HighHighest price in past year | $6.26 | $3.09 |
| 52-Week LowLowest price in past year | $0.64 | $0.05 |
| % of 52W HighCurrent price vs 52-week peak | +70.3% | +4.9% |
| RSI (14)Momentum oscillator 0–100 | 70.4 | 24.2 |
| Avg Volume (50D)Average daily shares traded | 38K | 901K |
Evenly matched — LIXT and CASI each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
CASI is the only dividend payer here at 31.10% yield — a key consideration for income-focused portfolios.
| Metric | LIXTLixte Biotechnolo… | CASICASI Pharmaceutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | +31.1% |
| Dividend StreakConsecutive years of raises | 0 | 0 |
| Dividend / ShareAnnual DPS | — | $0.05 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
LIXT leads in 2 of 6 categories (Income & Cash Flow, Total Returns). CASI leads in 1 (Profitability & Efficiency). 2 tied.
Best OverallLixte Biotechnology Holding… (LIXT)Leads 2 of 6 categories
Loading custom metrics...
LIXT vs CASI: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — LIXT or CASI?
Over the past 5 years, Lixte Biotechnology Holdings, Inc.
(LIXT) delivered a total return of -84. 4%, compared to -99. 1% for CASI Pharmaceuticals, Inc. (CASI). Over 10 years, the gap is even starker: LIXT returned -38. 9% versus CASI's -98. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — LIXT or CASI?
By beta (market sensitivity over 5 years), CASI Pharmaceuticals, Inc.
(CASI) is the lower-risk stock at -0. 12β versus Lixte Biotechnology Holdings, Inc. 's 1. 09β — meaning LIXT is approximately -991% more volatile than CASI relative to the S&P 500.
03Which is growing faster — LIXT or CASI?
On earnings-per-share growth, the picture is similar: Lixte Biotechnology Holdings, Inc.
grew EPS 40. 2% year-over-year, compared to -26. 7% for CASI Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — LIXT or CASI?
Lixte Biotechnology Holdings, Inc.
(LIXT) is the more profitable company, earning 0. 0% net margin versus -137. 6% for CASI Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LIXT leads at 0. 0% versus -138. 8% for CASI. At the gross margin level — before operating expenses — CASI leads at 39. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — LIXT or CASI?
In this comparison, CASI (31.
1% yield) pays a dividend. LIXT does not pay a meaningful dividend and should not be held primarily for income.
06Is LIXT or CASI better for a retirement portfolio?
For long-horizon retirement investors, CASI Pharmaceuticals, Inc.
(CASI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 12), 31. 1% yield). Both have compounded well over 10 years (CASI: -98. 9%, LIXT: -38. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between LIXT and CASI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: LIXT is a small-cap quality compounder stock; CASI is a small-cap income-oriented stock. CASI pays a dividend while LIXT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.